CA2724172C - Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections - Google Patents

Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections Download PDF

Info

Publication number
CA2724172C
CA2724172C CA2724172A CA2724172A CA2724172C CA 2724172 C CA2724172 C CA 2724172C CA 2724172 A CA2724172 A CA 2724172A CA 2724172 A CA2724172 A CA 2724172A CA 2724172 C CA2724172 C CA 2724172C
Authority
CA
Canada
Prior art keywords
iron
hydroxypyrone
subject
use according
gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2724172A
Other languages
English (en)
French (fr)
Other versions
CA2724172A1 (en
Inventor
Michael Arthur Stockham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shield Tx UK Ltd
Original Assignee
Iron Therapeutics Holdings AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iron Therapeutics Holdings AG filed Critical Iron Therapeutics Holdings AG
Publication of CA2724172A1 publication Critical patent/CA2724172A1/en
Application granted granted Critical
Publication of CA2724172C publication Critical patent/CA2724172C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2724172A 2008-05-15 2009-05-14 Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections Active CA2724172C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0808835.3 2008-05-15
GBGB0808835.3A GB0808835D0 (en) 2008-05-15 2008-05-15 Therapeutic compositions
PCT/GB2009/001231 WO2009138761A1 (en) 2008-05-15 2009-05-14 Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections

Publications (2)

Publication Number Publication Date
CA2724172A1 CA2724172A1 (en) 2009-11-19
CA2724172C true CA2724172C (en) 2017-07-25

Family

ID=39571409

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724172A Active CA2724172C (en) 2008-05-15 2009-05-14 Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections

Country Status (9)

Country Link
US (2) US9248148B2 (cg-RX-API-DMAC7.html)
EP (1) EP2303289A1 (cg-RX-API-DMAC7.html)
JP (2) JP5769308B2 (cg-RX-API-DMAC7.html)
CN (1) CN102099042B (cg-RX-API-DMAC7.html)
AU (1) AU2009247762B2 (cg-RX-API-DMAC7.html)
CA (1) CA2724172C (cg-RX-API-DMAC7.html)
GB (1) GB0808835D0 (cg-RX-API-DMAC7.html)
SG (1) SG182137A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009138761A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104829272A (zh) 2009-12-22 2015-08-12 拉尔科营养品有限公司 有机螯合的矿物组合物及其制备方法
GB201101370D0 (en) 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
CA3131334A1 (en) * 2012-07-05 2014-01-09 Ralco Nutrition, Inc. Agricultural compositions and applications utilizing mineral compounds
BR112016015766A2 (pt) 2014-01-06 2017-08-08 Iron Therapeutics Holdings Ag Regime de dosagem de trimaltol férrico
GB201404390D0 (en) * 2014-03-12 2014-04-23 Iron Therapeutics Holdings Ag Composition
RU2018121553A (ru) 2014-04-17 2019-03-06 Ралко Ньютришн, Инк. Сельскохозяйственные композиции и применения с использованием минеральных соединений
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
US11517540B2 (en) 2015-01-09 2022-12-06 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
JP2017032550A (ja) * 2015-07-30 2017-02-09 大塚製薬株式会社 胃粘膜萎縮の有無を判定する方法
AU2017242908B2 (en) * 2016-03-31 2022-11-17 Shield TX (UK) Limited Ferric maltol compositions for use in the treatment or prevention of cancer and tumours
GB2553099A (en) * 2016-08-19 2018-02-28 Shield Tx Uk Ltd Use
IT201700021676A1 (it) * 2017-02-28 2018-08-28 Carlo Angelo Ghisalberti Composizioni e sistemi di estrazione del ferro non-eme dalla dieta per uso nell’anemia sideropenica e carenze marziali

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128998B (en) * 1982-10-22 1986-07-16 Nat Res Dev Pharmaceutical compositions of iron complexes of 3 hydroxy-4-pyrone
US5177068A (en) 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
EP0833627B1 (en) 1995-06-10 2004-08-18 Vitra Pharmaceuticals Ltd. Iron compounds, compositions, methods of making the same and uses thereof
GB9621273D0 (en) * 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
GB0012487D0 (en) * 2000-05-24 2000-07-12 Pfylori Limited Use of metal compounds to treat gastrointestinal infections
CA2421410C (en) * 2000-09-19 2009-11-10 Vitra Pharmaceuticals Limited Iron compositions
GB0211500D0 (en) 2002-05-18 2002-06-26 Vitra Pharmaceuticals Ltd Method of forming iron hydroxypyrone compounds
EP1686982A4 (en) 2003-11-19 2007-03-21 Vecta Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI USING COMPOUNDS CONTAINING ENDOPEROXIDE BRIDGE
WO2007081744A2 (en) 2006-01-06 2007-07-19 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
WO2007108712A1 (en) 2006-03-17 2007-09-27 Tatyana Vyacheslavovna Popkova Kit and method for treating or preventing anemia caused by iron deficiency
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption

Also Published As

Publication number Publication date
US9248148B2 (en) 2016-02-02
US20160120902A1 (en) 2016-05-05
CA2724172A1 (en) 2009-11-19
EP2303289A1 (en) 2011-04-06
JP2015083572A (ja) 2015-04-30
CN102099042A (zh) 2011-06-15
JP2011520855A (ja) 2011-07-21
SG182137A1 (en) 2012-07-30
AU2009247762B2 (en) 2014-08-14
WO2009138761A1 (en) 2009-11-19
US20110177172A1 (en) 2011-07-21
JP5769308B2 (ja) 2015-08-26
CN102099042B (zh) 2014-08-13
GB0808835D0 (en) 2008-06-18
AU2009247762A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
US9248148B2 (en) Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections
US6197763B1 (en) Use of metal complexes to treat gastrointestinal infections
US20060134227A1 (en) Compositions including iron
EP1318804B1 (en) Iron compositions
CN101309685A (zh) 磷酸二酯酶ⅲ型抑制剂或者钙增敏剂用于治疗无症状(潜隐性)心力衰竭的用途
US6426369B1 (en) Oxethazaine as antimicrobial agent
AU776732B2 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines C
CN109310667B (zh) 用于治疗或预防癌症和肿瘤的麦芽酚铁组合物
HK1156552B (en) Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and gi inflammation inhibiting agents) compositions for anaemia or h. pylori infections
HK1156552A (en) Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and gi inflammation inhibiting agents) compositions for anaemia or h. pylori infections
WO2022187142A1 (en) Modulation of drug-drug interactions of vadadustat
Eddlestone Drug Therapies Used in Gastrointestinal
JP4081157B2 (ja) ヘリコバクター・ピロリ菌用抗菌剤
JP2000080031A (ja) 抗菌剤
JP2002029966A (ja) 抗ヘリコバクター・ピロリ剤
HK40004283A (en) Ferric maltol compositions for use in the treatment or prevention of cancer and tumours

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140512

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250505

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260504

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260504